Skip to main content
AIMD
NASDAQ Technology

Ainos Licenses VELDONA Platform to BioPhoenix for $600K Upfront, Up to $10M Framework

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.388
Mkt Cap
$9.895M
52W Low
$1.25
52W High
$4.44
52W Position info
11% above low
Off High info
69% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

AIMD is trading near its 52-week low of $1.25 (11% above the low).

Summary

Ainos granted BioPhoenix an exclusive worldwide license to its VELDONA platform for Sjögren's Disease and Thrombocytopenia, receiving a $600,000 upfront fee, 25% of net sublicensing revenue, and a potential $10 million framework if all additional indications are licensed.


Key Events · M&A and Partnerships · AIMD

  • Global Exclusive VELDONA License Signed

    Ainos granted BioPhoenix Co., Ltd. an exclusive, worldwide, irrevocable, transferable, sublicensable license to its VELDONA low-dose oral interferon alpha platform for Sjögren's Disease and Thrombocytopenia, including manufacturing rights.

  • $600K Upfront Fee, $10M Potential Framework

    BioPhoenix will pay a $600,000 upfront license fee due within 15 business days after technology transfer completion, plus a one-time first sublicense fee and 25% of net sublicensing revenue. If all 15 additional indications are licensed, total license fees could reach approximately $10.0 million.

  • Partner Funds Clinical and Regulatory Work

    BioPhoenix assumes funding and execution of assigned clinical and regulatory activities for the two licensed indications, reducing Ainos' need to independently finance development — a critical relief given Ainos' $1.4 million cash balance and going concern warning.

  • 10-Year Non-Compete and ROFR Granted

    Ainos cannot compete with the Licensed Indications worldwide during the term and for 10 years after termination. BioPhoenix also received a right of first refusal and call option on additional VELDONA indications that have progressed to Phase 2 clinical trials.


Analysis · AIMD · Technology

Ainos has monetized its VELDONA low-dose oral interferon alpha platform through a global exclusive license to Taiwan-based BioPhoenix for Sjögren's Disease and Thrombocytopenia. The deal brings a $600,000 upfront fee — nearly half of the $1.4 million in cash Ainos reported in August — plus 25% of net sublicensing revenue and a potential $10 million total framework if all 15 additional indications are licensed. Critically, BioPhoenix funds and executes all assigned clinical and regulatory work, which removes a major cash drain from Ainos at a time when the company is fighting a going concern warning. The trade-off is significant: Ainos grants an irrevocable, worldwide exclusive license and agrees not to compete in those indications for 10 years after the agreement ends. For a company with near-zero revenue and persistent going concern risk, this is a meaningful step toward survival and strategic focus on its AI Nose / Chemical Intelligence business.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AIMD was trading at $1.39 on NASDAQ in the Technology sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.25 to $4.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIMD - Latest Insights

AIMD
Nov 16, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.32
Real-time Price: $1.11 info
Change: -$0.204 (-16%) info
Market Cap: $9.839M info
AIMD
Nov 16, 2026, 8:30 AM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $1.30
Real-time Price: $1.11 info
Change: -$0.189 (-15%) info
Market Cap: $9.839M info
AIMD
Nov 12, 2026, 8:30 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.520
Real-time Price: $1.11 info
Change: +$0.591 (+114%) info
Market Cap: $9.839M info
AIMD
Nov 10, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.4693
Real-time Price: $1.11 info
Change: +$0.6417 (+137%) info
Market Cap: $9.839M info
AIMD
Sep 28, 2026, 8:00 AM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $1.11 info
Change: -$0.209 (-16%) info
Market Cap: $9.839M info